NCT04608786 - A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2023

Conditions

Biliary Tract Cancer

Interventions

DRUG

ZKAB001 5mg/kg

ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year

DRUG

Capecitabine

Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses

Trial Locations (1)

Unknown

Renji Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai